Press Release: MedHub-AI Appoints New Board Member

Developing and deploying AI where it matters most, Med-Hub harnesses AI “to enable precision cardiac care”. With its novel AutocathFFR™, an automated decision support system for interventional cardiologists, Medhub helps those who care for our hearts streamline their workflows and achieve the best possible outcomes, thereby reducing post-procedure adverse events and mortality, preventing unnecessary therapeutic procedures, and the necessity for additional invasive diagnostic interventions.

With its steady march forward and continuing growth, Medhub produces a steady steam of news, and often conveys these developments to its audience of clients, partners, and investors through press releases.

Collaborating with Or Baruch El, Medhub’s remarkable CEO, I helped translate and edit this announcement of the appointment of a new board member.

Great company, and great to work with.

Press Release Beginning

“MedHub Appoints Prof. Rafael Beyar, Co-Founder of Cordinus Vascular Robotics, to its Board of Directors
Sep 08, 2020, 07:00 ET

TEL AVIV, Israel, Sept. 8, 2020 /PRNewswire/ -- MedHub Ltd, a medical technology company specializing in the development and commercialization of AI powered technologies that aid in the diagnosis of cardiac disease, announced today the appointment of Prof. Rafael Beyar as the Chairman of the company's Board of Directors.

As MedHub continues to execute on its go-to-market strategy, the company is further expanding its capabilities and expertise with the appointment of Prof. Rafael Beyar, a seasoned medical device and robotics entrepreneur with a proven track record of helping small and medium sized companies gain a leading market position.

"We are thrilled to have a leading industry expert, with Prof. Beyar's extensive medical device development expertise, join our Board of Directors," said Or Baruch El, Chief Executive Officer of MedHub. "Prof. Beyar is a distinguished cardiologist and medical-device entrepreneur known worldwide for his ceaseless innovations and stewardship of successful med-tech companies. His insights will be instrumental as we roll-out our marketing program and invest in collaboration opportunities."